Shaobo Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaobo Hu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Guoliang Wang
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China
2 shared publicationsJianjun Xu
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China
2 shared publicationsWenqiang Wang
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China
2 shared publicationsChen Zhang
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Liver Transplant Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
1 shared publication- Chen Zhang
Liver transplant center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication Fang Huang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
1 shared publication
Latest Publications
- Open Access
- 30 March 2026
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (5) , 1-22
Identification of STMN1 as a lactylation‑related driver of lung cancer progression using Mendelian randomization
Lung cancer is an aggressive malignancy associated with a rapid progression and poor prognosis, for which immunotherapy only exhibits modest efficacy in most patients. In lung cancer, high lactate is associated with a low immunotherapy response and shortened survival; however, causal lactylation‑related genes remain to be elucidated. In the present study, candidate genes were screened using Mendelian randomization (MR) analysis, with expression quantitative trait loci data and genome‑wide association study summary statistics used as analytical resources. A total of 46 lactylation‑related genes were included in the MR analysis, and multiple testing correction was performed using the false discovery rate (FDR) and Bonferroni methods to control the false‑positive risk. MR identified three core genes [platelet‑type phosphofructokinase; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; and stathmin 1 (STMN1)]. Among these genes, only STMN1 was significantly associated with increased lung cancer risk (inverse variance weighting original P=0.005, FDR‑corrected P=0.014995, Bonferroni‑corrected P=0.014995, odds ratio=1.741, 95% confidence interval: 1.182‑2.564), with robust results confirmed by heterogeneity/pleiotropy/sensitivity analyses. Subsequently, transcriptomic analysis was conducted to assess STMN1 expression in lung cancer tissues and its association with patient survival. In vitro (cell proliferation, migration, invasion and apoptosis assays) and in vivo experiments (murine tumor models) were also conducted to explore the function of STMN1. STMN1 exhibited upregulation in lung cancer tissues, and was associated with a shorter survival, reduced antitumor immune cell infiltration and an immunosuppressive tumor microenvironment (TME) phenotype. STMN1 knockdown inhibited lung cancer malignancy both in vitro and in vivo, and modulated key markers, whereas its overexpression exhibited the opposite effects. Additionally, STMN1 promoted global histone lactylation and histone H3 lysine 18 lactylation in lung cancer cells, establishing a direct functional link between STMN1 and the lactylation pathway. In conclusion, STMN1 is a lactylation‑related causal oncogene in lung cancer, driving progression via malignant phenotypes, and its high expression is associated with an immunosuppressive TME that may synergistically facilitate tumor progression. Therefore, STMN1 may be considered a novel target for lung cancer therapy.
- 30 March 2026
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (5) , 1-22
Open AccessIdentification of STMN1 as a lactylation‑related driver of lung cancer progression using Mendelian randomization
Lung cancer is an aggressive malignancy associated with a rapid progression and poor prognosis, for which immunotherapy only exhibits modest efficacy in most patients. In lung cancer, high lactate is associated with a low immunotherapy response and shortened survival; however, causal lactylation‑related genes remain to be elucidated. In the present study, candidate genes were screened using Mendelian randomization (MR) analysis, with expression quantitative trait loci data and genome‑wide association study summary statistics used as analytical resources. A total of 46 lactylation‑related genes were included in the MR analysis, and multiple testing correction was performed using the false discovery rate (FDR) and Bonferroni methods to control the false‑positive risk. MR identified three core genes [platelet‑type phosphofructokinase; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; and stathmin 1 (STMN1)]. Among these genes, only STMN1 was significantly associated with increased lung cancer risk (inverse variance weighting original P=0.005, FDR‑corrected P=0.014995, Bonferroni‑corrected P=0.014995, odds ratio=1.741, 95% confidence interval: 1.182‑2.564), with robust results confirmed by heterogeneity/pleiotropy/sensitivity analyses. Subsequently, transcriptomic analysis was conducted to assess STMN1 expression in lung cancer tissues and its association with patient survival. In vitro (cell proliferation, migration, invasion and apoptosis assays) and in vivo experiments (murine tumor models) were also conducted to explore the function of STMN1. STMN1 exhibited upregulation in lung cancer tissues, and was associated with a shorter survival, reduced antitumor immune cell infiltration and an immunosuppressive tumor microenvironment (TME) phenotype. STMN1 knockdown inhibited lung cancer malignancy both in vitro and in vivo, and modulated key markers, whereas its overexpression exhibited the opposite effects. Additionally, STMN1 promoted global histone lactylation and histone H3 lysine 18 lactylation in lung cancer cells, establishing a direct functional link between STMN1 and the lactylation pathway. In conclusion, STMN1 is a lactylation‑related causal oncogene in lung cancer, driving progression via malignant phenotypes, and its high expression is associated with an immunosuppressive TME that may synergistically facilitate tumor progression. Therefore, STMN1 may be considered a novel target for lung cancer therapy.
- 5 August 2025
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 172 (8)
Circulating Tumor DNA Methylation with Photoelectrochemical Sensor Signatures Decoded by Attention Mechanisms
Integration of ultrasensitive photoelectrochemical (PEC) sensing with advanced computational analysis presents a novel approach for early cancer detection through circulating tumor DNA (ctDNA) methylation profiling. We report a synergistic platform combining BiOBr/WS2 heterojunction–based PEC sensor with attention–driven deep learning to decode cancer–specific methylation signatures. The BiOBr/WS2 composite, synthesized via a two–step hydrothermal process, demonstrated enhanced visible–light absorption and charge separation efficiency, achieving a 2.3–fold higher photocurrent response than pristine BiOBr. This sensor enabled ultrasensitive ctDNA detection with a linear range spanning six orders of magnitude (0.5 fM to 500 pM) and an ultralow detection limit of 0.05 fM. Deep learning revealed that attention mechanisms prioritized methylation loci in promoter regions and gene bodies, achieving 75% classification accuracy and a ROC AUC of 0.889. The model identified bidirectional methylation patterns, with 73% of high–weight CpG sites showing cancer–specific hypomethylation, challenging traditional hypermethylation–centric paradigms. The sensor exhibited exceptional selectivity against mismatched sequences, 95% signal stability over 7 days, and 97–103% recovery in human serum. By bridging nanomaterial–enhanced PEC transduction with context–aware methylation analysis, this work establishes robust framework for non–invasive cancer screening, emphasizing the critical role of epigenetic heterogeneity in early intervention strategies.
- 5 August 2025
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 172 (8)
Circulating Tumor DNA Methylation with Photoelectrochemical Sensor Signatures Decoded by Attention Mechanisms
Integration of ultrasensitive photoelectrochemical (PEC) sensing with advanced computational analysis presents a novel approach for early cancer detection through circulating tumor DNA (ctDNA) methylation profiling. We report a synergistic platform combining BiOBr/WS2 heterojunction–based PEC sensor with attention–driven deep learning to decode cancer–specific methylation signatures. The BiOBr/WS2 composite, synthesized via a two–step hydrothermal process, demonstrated enhanced visible–light absorption and charge separation efficiency, achieving a 2.3–fold higher photocurrent response than pristine BiOBr. This sensor enabled ultrasensitive ctDNA detection with a linear range spanning six orders of magnitude (0.5 fM to 500 pM) and an ultralow detection limit of 0.05 fM. Deep learning revealed that attention mechanisms prioritized methylation loci in promoter regions and gene bodies, achieving 75% classification accuracy and a ROC AUC of 0.889. The model identified bidirectional methylation patterns, with 73% of high–weight CpG sites showing cancer–specific hypomethylation, challenging traditional hypermethylation–centric paradigms. The sensor exhibited exceptional selectivity against mismatched sequences, 95% signal stability over 7 days, and 97–103% recovery in human serum. By bridging nanomaterial–enhanced PEC transduction with context–aware methylation analysis, this work establishes robust framework for non–invasive cancer screening, emphasizing the critical role of epigenetic heterogeneity in early intervention strategies.
- 22 May 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 212, 104774
A review of the role of CSCs and CSC-EXOs in increasing drug resistance in breast cancer and future applications
- 22 May 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 212, 104774
A review of the role of CSCs and CSC-EXOs in increasing drug resistance in breast cancer and future applications